Shankar Siva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8540870/publications.pdf

Version: 2024-02-01

182	6,536	66234	79541
papers	citations	42 h-index	73 g-index

184	184	184	7010
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treatment Reviews, 2015, 41, 503-510.	3.4	482
2	Radiotherapy toxicity. Nature Reviews Disease Primers, 2019, 5, 13.	18.1	434
3	Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Letters, 2015, 356, 82-90.	3.2	354
4	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology, 2018, 74, 455-462.	0.9	250
5	Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review. Journal of Thoracic Oncology, 2010, 5, 1091-1099.	0.5	206
6	Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncology, The, 2021, 22, 1023-1033.	5.1	183
7	Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer, 2018, 124, 934-942.	2.0	125
8	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology, 2020, 77, 365-372.	0.9	116
9	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. JAMA Oncology, 2021, 7, 92.	3.4	114
10	A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU International, 2012, 110, E737-43.	1.3	108
11	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European Urology, 2019, 76, 732-739.	0.9	99
12	Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. European Urology Oncology, 2019, 2, 515-523.	2.6	97
13	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022, 40, 2957-2995.	0.8	97
14	Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nature Reviews Urology, 2017, 14, 549-563.	1.9	88
15	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	1.6	86
16	Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU International, 2017, 120, 623-630.	1.3	85
17	18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience. Journal of Nuclear Medicine, 2013, 54, 1223-1229.	2.8	84
18	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. Radiotherapy and Oncology, 2015, 115, 157-162.	0.3	83

#	Article	IF	Citations
19	Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review. Acta OncolÃ³gica, 2015, 54, 148-157.	0.8	83
20	Utility of ⁶⁸Ga prostate specific membrane antigen â€“ positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 372-378.	0.9	83
21	A Pattern of Early Radiation-Induced Inflammatory Cytokine Expression Is Associated with Lung Toxicity in Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e109560.	1.1	81
22	Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers, 2015, 7, 981-1004.	1.7	81
23	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using ⁶⁸ Ga-labeled nanoparticles. Medical Physics, 2013, 41, 011910.	1.6	79
24	Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e71-e72.	0.5	78
25	Surgical and ablative therapies for the management of adrenal â€˜oligometastasesâ€™ â€“ A systematic review. Cancer Treatment Reviews, 2014, 40, 838-846.	3.4	72
26	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinomaâ€”The RAPPORT Trial. European Urology, 2022, 81, 364-372.	0.9	70
27	Mobilization of Viable Tumor Cells Into the Circulation During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 395-403.	0.4	67
28	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 625-631.	2.8	62
29	Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a doseâ€“response relationship. Radiotherapy and Oncology, 2016, 118, 540-546.	0.3	60
30	Stereotactic Ablative Body Radiation Therapy forÂPrimary Kidney Cancer: A 3-Dimensional Conformal Technique Associated With Low Rates of Early Toxicity. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1061-1068.	0.4	58
31	Impact of postâ€therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer, 2011, 117, 3981-3988.	2.0	57
32	Radiotherapy for Nonâ€“Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues. Clinical Cancer Research, 2016, 22, 4817-4826.	3.2	57
33	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncology, 2016, 12, 637-645.	1.1	56
34	Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2018, 129, 196-208.	0.3	53
35	Radiotherapy and immunotherapy: a synergistic effect in cancer care. Medical Journal of Australia, 2019, 210, 47-53.	0.8	53
36	Immunological markers that predict radiation toxicity. Cancer Letters, 2015, 368, 191-197.	3.2	50

#	Article	IF	Citations
37	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer, 2018, 18, 1030.	1.1	50
38	Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncology, 2021, 7, 1476.	3.4	50
39	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast, 2020, 49, 55-62.	0.9	49
40	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. Clinical Oncology, 2019, 31, 432-443.	0.6	48
41	Stereotactic Ablative Radiotherapy for â‰¥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 941-949.	0.4	48
42	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. Seminars in Nuclear Medicine, 2019, 49, 71-81.	2.5	47
43	An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiation Oncology, 2013, 8, 248.	1.2	43
44	High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 343-349.	3.3	43
45	Estimating lung ventilation directly from 4D CT Hounsfield unit values. Medical Physics, 2015, 43, 33-43.	1.6	42
46	Ventilation/Perfusion Positron Emission Tomographyâ€"Based Assessment of Radiation Injury to Lung. International Journal of Radiation Oncology Biology Physics, 2015, 93, 408-417.	0.4	41
47	Oligometastatic prostate cancer: The game is afoot. Cancer Treatment Reviews, 2019, 73, 84-90.	3.4	41
48	Expanding the role of small-molecule PSMA ligands beyond PET staging ofÂprostate cancer. Nature Reviews Urology, 2020, 17, 107-118.	1.9	41
49	Guidelines for safe practice of stereotactic body (ablative) radiation therapy. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 646-653.	0.9	37
50	A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy. Radiotherapy and Oncology, 2021, 155, 188-203.	0.3	37
51	Validation of a 4D-PET Maximum Intensity Projection for Delineation of an Internal Target Volume. International Journal of Radiation Oncology Biology Physics, 2013, 86, 749-754.	0.4	36
52	68 Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate International, 2017, 5, 125-129.	1.2	36
53	Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. Radiation Oncology, 2014, 9, 291.	1.2	34
54	A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). BMC Cancer, 2016, 16, 183.	1.1	34

#	Article	IF	Citations
55	Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. European Urology, 2022, 81, 253-262.	0.9	34
56	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. Technology in Cancer Research and Treatment, 2016, 15, 114-121.	0.8	33
57	Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases. Clinical Oncology, 2017, 29, e119-e125.	0.6	33
58	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 530-538.	0.4	33
59	⁶⁸Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional ⁵¹Cr-EDTA. Journal of Nuclear Medicine, 2015, 56, 405-409.	2.8	32
60	Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer. Medicine (United States), 2016, 95, e2488.	0.4	32
61	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. Clinical and Translational Radiation Oncology, 2019, 18, 104-112.	0.9	30
62	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Radiographics, 2021, 41, 1387-1407.	1.4	30
63	Correlation of ⁶⁸Ga Ventilationâ€“Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. Journal of Nuclear Medicine, 2015, 56, 1718-1723.	2.8	29
64	Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?. Advances in Radiation Oncology, 2020, 5, 761-773.	0.6	28
65	Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncology, 2014, 10, 761-774.	1.1	27
66	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1219.	1.3	27
67	The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. European Urology, 2022, 82, 613-622.	0.9	27
68	Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial 99mTc-DMSA SPECT/CT. Radiation Oncology, 2014, 9, 253.	1.2	26
69	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. BMC Cancer, 2014, 14, 740.	1.1	26
70	15-Year Experience of ¹⁸F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1328-1333.	2.8	26
71	Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?. Seminars in Radiation Oncology, 2017, 27, 229-239.	1.0	26
72	What ¹⁸F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Nonâ€“Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. Journal of Nuclear Medicine, 2019, 60, 328-334.	2.8	24

#	Article	IF	Citations
73	Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Practical Radiation Oncology, 2020, 10, e452-e460.	1.1	24
74	Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. Journal of Urology, 2019, 201, 1097-1104.	0.2	24
75	A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography Images. Frontiers in Oncology, 2021, 11, 580806.	1.3	22
76	Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. Cancers, 2022, 14, 790.	1.7	22
77	18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1825-1832.	3.3	21
78	Accuracy and Utility of Deformable Image Registration in 68Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 196-204.	0.4	21
79	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU International, 2021, 127, 703-711.	1.3	20
80	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the â€˜TOaSTTâ€™ database. Radiation Oncology, 2021, 16, 4.	1.2	20
81	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. European Urology Focus, 2021, 7, 241-244.	1.6	20
82	A Patient-Level Data Meta-analysis of the Abscopal Effect. Advances in Radiation Oncology, 2022, 7, 100909.	0.6	20
83	Automatic delineation of functional lung volumes with 68Ga-ventilation/perfusion PET/CT. EJNMMI Research, 2017, 7, 82.	1.1	19
84	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1869-1877.	3.3	19
85	Vacuum immobilisation reduces tumour excursion and minimises intrafraction error in a cohort study of stereotactic ablative body radiotherapy for pulmonary metastases. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 244-252.	0.9	18
86	Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 308-321.	0.7	18
87	Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients. Clinical Oncology, 2018, 30, 178-184.	0.6	18
88	TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol. BMJ Open, 2019, 9, e030731.	0.8	18
89	Bronchoscopic Delivery of Lipiodol as a Fiducial Marker in Lung Tumors Before Radiotherapy. Journal of Thoracic Oncology, 2014, 9, 1579-1583.	0.5	17
90	Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases. International Journal of Radiation Oncology Biology Physics, 2021, 109, 756-763.	0.4	17

#	Article	IF	Citations
91	The Epidemiology of Lung Metastases. Frontiers in Medicine, 2021, 8, 723396.	1.2	17
92	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e9-166.e13.	0.8	17
93	Implementation of a lung radiosurgery program: Technical considerations and quality assurance in an Australian institution. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 354-361.	0.9	16
94	Stereotactic Body Radiotherapy for Primary Prostate Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381878963.	0.8	16
95	Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. Chinese Clinical Oncology, 2017, 6, S17-S17.	0.4	16
96	The Use of Dual Vacuum Stabilization Device to Reduce Kidney Motion for Stereotactic Radiotherapy Planning. Technology in Cancer Research and Treatment, 2015, 14, 149-157.	0.8	15
97	Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. PLoS ONE, 2018, 13, e0202387.	1.1	15
98	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 572-579.	0.6	15
99	Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer. BMJ Open, 2020, 10, e042465.	0.8	15
100	Conventional margins not sufficient for post-prostatectomy prostate bed coverage: An analysis of 477 cone-beam computed tomography scans. Radiotherapy and Oncology, 2014, 110, 235-239.	0.3	14
101	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. Acta OncolÃ³gica, 2015, 54, 1105-1112.	0.8	14
102	Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in non-small cell lung cancer. ERJ Open Research, 2019, 5, 00004-2019.	1.1	13
103	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	0.5	13
104	Ten-year results of quality assurance in radiotherapy chart round. BMC Health Services Research, 2013, 13, 148.	0.9	12
105	Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens. Oncologist, 2016, 21, 393-398.	1.9	12
106	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 1-5.	0.9	12
107	NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiation Oncology, 2019, 14, 164.	1.2	12
108	Practical Assessment of Bronchoscopically Inserted Fiducial Markers for Image Guidance in Stereotactic Lung Radiotherapy. Journal of Thoracic Oncology, 2016, 11, 1363-1368.	0.5	11

#	Article	IF	Citations
109	The great debate flashes: surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. European Journal of Cardio-thoracic Surgery, 2018, 53, 295-305.	0.6	11
110	Radiation Therapy Modulates DNA Repair Efficiency in Peripheral Blood Mononuclear Cells of Patients With Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 521-531.	0.4	11
111	Independent review of 4DCT scans used for SABR treatment planning. Journal of Applied Clinical Medical Physics, 2020, 21, 62-67.	0.8	11
112	An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 2021, 6, 100653.	0.6	11
113	Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. Journal of Thoracic Oncology, 2018, 13, 488-496.	0.5	10
114	Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: A case study. Medical Dosimetry, 2013, 38, 304-308.	0.4	9
115	Results of patient specific quality assurance for patients undergoing stereotactic ablative radiotherapy for lung lesions. Australasian Physical and Engineering Sciences in Medicine, 2014, 37, 45-52.	1.4	9
116	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. Journal of Thoracic Oncology, 2015, 10, 1112-1115.	0.5	9
117	Single Fraction SBRT for Early Stage Lung Cancerâ€"Less is More?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1085-1087.	0.4	9
118	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. Current Oncology Reports, 2019, 21, 43.	1.8	9
119	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778.	1.3	9
120	The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncology, 2015, 11, 2721-2733.	1.1	8
121	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. Clinical and Translational Radiation Oncology, 2017, 2, 53-58.	0.9	8
122	Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients. Cancers, 2020, 12, 2517.	1.7	8
123	Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. Radiation Oncology, 2021, 16, 142.	1.2	8
124	International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2022, 112, 351-360.	0.4	8
125	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	1.7	8
126	<scp>CT</scp> perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 207-215.	0.9	7

#	Article	IF	Citations
127	Image guidance and stabilization for stereotactic ablative body radiation therapy (SABR) treatment of primary kidney cancer. Practical Radiation Oncology, 2015, 5, e597-e605.	1.1	7
128	Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 677-685.	0.9	7
129	The Prickly Predicament of Pursuing Pulmonary Polymetastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, 764-765.	0.4	7
130	The challenge of planning vertebral body SBRT: Optimizing target volume coverage. Medical Dosimetry, 2020, 45, 302-307.	0.4	7
131	Local ablative therapies in oligometastatic NSCLC-upfront or outback?â€"a narrative review. Translational Lung Cancer Research, 2021, 10, 3446-3456.	1.3	7
132	Stereotactic ablative body radiotherapy for primary kidney cancer: what have we learned from prospective trials and what does the future hold?. Future Oncology, 2016, 12, 601-606.	1.1	6
133	Novel agents for metastatic hormoneâ€sensitive prostate cancer â€“ a practice guide for urologists. BJU International, 2020, 125, 342-345.	1.3	6
134	A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemporary Clinical Trials Communications, 2021, 21, 100703.	0.5	6
135	SABR in oligometastatic breast cancer: Current status and future directions. Breast, 2021, 60, 223-229.	0.9	6
136	Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis. Radiotherapy and Oncology, 2022, 173, 163-169.	0.3	6
137	Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 450-461.	3.9	5
138	Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report. BMC Cancer, 2019, 19, 671.	1.1	5
139	Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Physica Medica, 2020, 72, 16-21.	0.4	5
140	On the reduction of aperture complexity in kidney SABR. Journal of Applied Clinical Medical Physics, 2021, 22, 71-81.	0.8	5
141	Surgery versus SABR for early-stage lung cancerâ€"time to call it a draw?. Lancet Oncology, The, 2021, 22, 1355-1357.	5.1	5
142	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines, 2022, 10, 821.	1.4	5
143	Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. Frontiers in Oncology, 2022, 12, 854589.	1.3	5
144	Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. International Journal of Radiation Oncology Biology Physics, 2022, 114, 862-870.	0.4	5

#	Article	IF	Citations
145	Adverse respiratory outcomes following conventional longâ€course radiotherapy for nonâ€smallâ€cell lung cancer in patients with preâ€existing pulmonary fibrosis: A comparative retrospective study. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 546-555.	0.9	4
146	Singleâ€fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 580-585.	0.9	4
147	Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. EJNMMI Physics, 2021, 8, 23.	1.3	4
148	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. Value in Health, 2021, 24, 1737-1745.	0.1	4
149	SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. Annals of Translational Medicine, 2019, 7, 615-615.	0.7	4
150	Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. Physics and Imaging in Radiation Oncology, 2022, 22, 8-12.	1.2	4
151	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiotherapy and Oncology, 2022, 172, 1-9.	0.3	4
152	Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. International Journal of Radiation Oncology Biology Physics, 2022, 114, 968-976.	0.4	4
153	Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Lung Cancer, 2022, 170, 185-193.	0.9	4
154	Analysis of the impact of chest wall constraints on eligibility for a randomized trial of stereotactic body radiotherapy of peripheral stage <scp>I</scp> nonâ€small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 654-660.	0.9	3
155	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanioâ€™s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus, 2021, 7, 494-495.	1.6	3
156	Reducing the impact on renal function of kidney SABR through management of respiratory motion. Physica Medica, 2021, 89, 72-79.	0.4	3
157	Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma â€" buying time or time to change?. Nature Reviews Urology, 2022, 19, 197-198.	1.9	3
158	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). Clinical Genitourinary Cancer, 2022, 20, e353-e361.	0.9	3
159	Inflammation and Oxidative DNA Damage. , 2014, , 63-74.		2
160	Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer. Cancer, 2016, 122, 322-323.	2.0	2
161	The Importance of Quasi-4D Path-Integrated Dose Accumulation for More Accurate Risk Estimation in Stereotactic Liver Radiotherapy. Technology in Cancer Research and Treatment, 2016, 15, 428-436.	0.8	2
162	Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. â€œGotta Catch 'em Allâ€•or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1â€“3.. European Urology, 2017, 72, e66-e67.	0.9	2

#	Article	IF	Citations
163	A planning study investigating dual-gated volumetric arc stereotactic treatment of primary renal cell carcinoma. Medical Dosimetry, 2015, 40, 82-88.	0.4	1
164	Australia and New Zealand Faculty of Radiation Oncology Lung Interest Cooperative: 2015 consensus guidelines for the use of advanced technologies in the radiation therapy treatment of locally advanced nonâ€small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 686-692.	0.9	1
165	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. European Urology, 2017, 72, 320.	0.9	1
166	Assessing the Clinical Utility of Computed Tomographyâ€Based Radiomics. Oncologist, 2018, 23, 747-749.	1.9	1
167	Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1197-1197.	0.7	1
168	Radiation is not the Ideal Solution. International Journal of Radiation Oncology Biology Physics, 2021, 109, 7-8.	0.4	1
169	Trend in Stereotactic Radiation Therapy Use for Management of Bone and Brain Metastases in Patients with Renal Cell Carcinoma in Australia. Oncologist, 2021, 26, e1288-e1289.	1.9	1
170	Functional and patientâ€reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limitedâ€stage smallâ€cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 786-795.	0.9	1
171	Nodal metabolic tumour volume on baseline 18 Fâ€FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curativeâ€intent chemoradiotherapy/radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 748-754.	0.9	1
172	Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. European Urology, 2021, 80, 701-702.	0.9	1
173	Inflammation and oxidatively induced DNA damage: A synergy leading to cancer development. , 2021, , 131-147.		1
174	Stereotactic body radiotherapy for oligometastatic renal cell carcinomaâ€”are we ready to roll?. Annals of Translational Medicine, 2019, 7, S180-S180.	0.7	1
175	Paraneoplastic encephalomyelitis associated with motor neuron disease causing respiratory failure in the setting of occult small cell lung carcinoma. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 118-121.	0.7	0
176	Stereotactic Body Radiotherapy. Medical Radiology, 2017, , 323-395.	0.0	0
177	Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum. International Journal of Radiation Oncology Biology Physics, 2017, 98, 494-495.	0.4	0
178	Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study. BMJ Open, 2021, 11, e051665.	0.8	0
179	Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS. European Urology, 2021, 80, 415-416.	0.9	0
180	Radiation Therapy for Renal Cell Carcinoma. Practical Guides in Radiation Oncology, 2021, , 301-312.	0.0	0

#	Article	IF	Citations
181	Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer. Lancet Oncology, The, 2022, 23, 443-444.	5.1	0
182	Assessing organ at risk position variation and its impact on delivered dose in kidney SABR. Radiation Oncology, 2022, 17, .	1.2	0